Glow in Seoul

Name decoder · Injectable

Re2O: an injectable made from donated human skin

리투오

Checked 2026-10-22. Prepared with AI assistance from the sources listed below; not reviewed by a doctor. Not medical advice.

리투오 (Re2O, sold as Elravie Re2O) is an injectable made by the Korean company L&C Bio from donated human skin with the cells removed, finely milled.[1][2] It is sold in Korea as a human-tissue product (인체조직), not a medical device.[3]

Published evidence is one small 2026 trial, and Korea’s drug regulator is re-examining the rules for this kind of product.[4][5]

At a glance

Maker
L&C Bio (엘앤씨바이오), Korea[1]
Brand
Elravie Re2O. Elravie is Humedix’s brand; Humedix and L&C Bio signed a deal for it in November 2024.[6]
Material
Milled human dermis with the cells removed (hADM)[1]
Versions
Re2O (150 mg) and Re2O Fine (50 mg)[1]
Launched
November 2024[7]
Category in Korea
Human tissue (인체조직) on the maker’s product list; the intended-use field on its product page is empty.[1][3]
Regulation
Sold as human tissue. In October 2026 the ministry was studying the rules for this product type; no product-specific decision was announced.[5]
Published evidence
One 20-person split-face trial of Re2O mixed with hyaluronic acid (2026).[4]
Also called
Elravie Re2O
Models and versions
Re2O Fine (50 mg version)

In Korean searches

Among the 33 treatments we track on Naver, Re2O ranks #12 by Korean search interest (index 13; the most-searched = 100). Too few related search terms to break down what people ask. Google searches in Korea for its main Korean name: +50% in Jul 2026–Sep 2026 compared with Oct 2025–Dec 2025.

From the Korea Treatment Radar, October 2026. Search interest, not treatments performed.

Why it is in the news

At the October 2026 National Assembly audit, the head of Korea’s Ministry of Food and Drug Safety said that, as far as the ministry understood, it had not approved such products for cosmetic purposes. The ministry is running a policy study on how much processing human tissue can undergo and still count as human tissue, and plans to revise its safety rules afterwards; it has not decided to reclassify any of these boosters as medical devices.[5]

Korean media reported in October 2026 that the ministry asked tissue banks to refrain from promotional or advertising wording, and that the health minister said the ministry was looking at whether to manage such products as medical devices.[8] Korea’s human-tissue rules contain no advertising rules, the ministry head noted.[5]

A lawmaker cited online reports of inflammation, lumps, redness and swelling and raised questions about leftover processing detergent or DNA; the same report notes these accounts alone do not show that any product is unsafe.[5]

What the one trial measured

One small trial has been published: 20 adults, 20 weeks, split-face and double-blinded, comparing Re2O mixed with a hyaluronic-acid booster against the hyaluronic-acid booster alone. The Re2O side improved more on several skin measures, with only mild, short-lived redness and swelling reported; the authors call it preliminary, and one author advised on the product’s development.[4]

Not the same as

  • Elravie hyaluronic-acid products, such as the Elravie Balance booster used as the comparison in the 2026 trial: same brand name, different material.[4]
  • Other donor-skin products, such as the same maker’s MegaFill and WonderFill, or 셀르디엠 from another company.
  • Rejuran (PN) and PDRN boosters: made from salmon DNA fragments, not human tissue.

Questions to ask the clinic

  1. Is this Re2O or Re2O Fine? Can I see the box and the lot label?
  2. What is it made of, and how is the donor tissue screened and traced?
  3. What reactions have you seen, and what do you do if a lump forms?
  4. Is it approved for the use you are suggesting?

Sources

  1. L&C Bio: Re2O product page, checked October 22, 2026↩1↩2↩3↩4↩5
  2. Medical Times, August 11, 2026: donor-skin injectables↩
  3. L&C Bio: product list by category, checked October 22, 2026↩1↩2
  4. Int J Mol Sci 2026;27(5):2193, published February 26, 2026: randomized, split-face, double-blind trial of Elravie Re2O mixed with HA vs HA alone (n=20, 20 weeks)↩1↩2↩3↩4
  5. Dailypharm, October 14, 2026: MFDS to re-examine the management of ECM skin boosters (National Assembly audit)↩1↩2↩3↩4↩5
  6. Medipharm Health: Humedix and L&C Bio Elravie Re2O agreement↩
  7. Hankyung, March 24, 2026: L&C Bio launch and facility permit↩
  8. MTN, October 13, 2026: MFDS letter to tissue banks; health minister on device classification↩

Manufacturer pages establish what a product is, not that it works. Regulatory filings describe what a regulator cleared or approved in that country. Glow in Seoul editorial; no clinic paid for or reviewed this page. See our transparency page.